Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

ABSTRACT: Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin’s lymphoma (NHL).

DISEASE(S): Cervical Cancer,Melanoma,Gastric Cancer,Non-small Cell Lung Cancer,Esophageal Cancer,Prostate Cancer,Cutaneous Squamous Cell Carcinoma,Solid Tumors,Neoplasms,Endometrial Carcinoma,Hepatocellular Carcinoma

PROVIDER: 2204683 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR